These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30730668)

  • 1. Carfilzomib (Kyprolis°) in multiple myeloma.
    Prescrire Int; 2017 May; 26(182):120. PubMed ID: 30730668
    [No Abstract]   [Full Text] [Related]  

  • 2. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple myeloma: new uses for available agents, excitement for the future.
    Anderson KC
    J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):694-6. PubMed ID: 25995433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of carfilzomib in the treatment of multiple myeloma.
    Khan RZ; Badros A
    Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carfilzomib in multiple myeloma.
    Andreu-Vieyra C; Berenson JR
    Expert Opin Biol Ther; 2014 Nov; 14(11):1685-99. PubMed ID: 25170966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A practical review on carfilzomib in multiple myeloma.
    Muchtar E; Gertz MA; Magen H
    Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carfilzomib: a novel agent for multiple myeloma.
    Redic K
    J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
    McBride A; Klaus JO; Stockerl-Goldstein K
    Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibitors: structure and function.
    Nunes AT; Annunziata CM
    Semin Oncol; 2017 Dec; 44(6):377-380. PubMed ID: 29935898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
    Bilotti E
    Clin J Oncol Nurs; 2013 Apr; 17(2):E35-44. PubMed ID: 23538263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
    Jakubowiak AJ
    Cancer Treat Rev; 2014 Jul; 40(6):781-90. PubMed ID: 24630735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of carfilzomib combination therapy in the management of multiple myeloma.
    Moreau P
    Expert Rev Hematol; 2014 Apr; 7(2):265-90. PubMed ID: 24521249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis.
    Shah C; Bishnoi R; Jain A; Bejjanki H; Xiong S; Wang Y; Zou F; Moreb JS
    Leuk Lymphoma; 2018 Nov; 59(11):2557-2569. PubMed ID: 29465266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation.
    Kint NG; Heylen E; Pepe D; De Keersmaecker K; Verfaillie CM; Delforge M
    Leukemia; 2020 Feb; 34(2):651-655. PubMed ID: 31467428
    [No Abstract]   [Full Text] [Related]  

  • 15. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
    Ikoma T; Saotome M; Sano M; Suwa K; Naruse Y; Ohtani H; Urushida T; Nagata Y; Ono T; Maekawa Y
    Intern Med; 2019 Jun; 58(11):1577-1581. PubMed ID: 30713316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.
    Vij R; Wang M; Jagannath S; Niesvizky R; Jakubowiak AJ; Kavalerchik E; Huang M; Siegel DS
    Leuk Lymphoma; 2015; 56(10):2959-61. PubMed ID: 25699653
    [No Abstract]   [Full Text] [Related]  

  • 18. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.
    Badros AZ; Vij R; Martin T; Zonder JA; Kunkel L; Wang Z; Lee S; Wong AF; Niesvizky R
    Leukemia; 2013 Aug; 27(8):1707-14. PubMed ID: 23364621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
    Stewart AK
    Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma.
    Squifflet P; Michiels S; Siegel D; Vij R; Jagannath S; Saad ED; Rajangam K; Ro SK; Buyse M
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):680-6. PubMed ID: 26482107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.